en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background:</span></span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Inflammatory breast cancer (IBC) is an aggressive subtype of breast carcinoma for which radiotherapy (RT) is a recommended treatment. This retrospective analysis aimed to clarify the impact of RT on survival outcomes among patients with IBC, stratified by molecular subtype. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Data concerning IBC patients diagnosed from 2010 through 2015 was based on the SEER (Surveillance, Epidemiology, and End Results) database. To evaluate survival differences among women with diverse molecular subtypes, comparisons were drawn between those treated with RT and those untreated, employing Cox proportional hazards modeling, Kaplan-Meier (KM) curves, and chi-square analysis. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">The cohort included 532 female patients, of whom 263 (49.4%) received radiotherapy. Nodal involvement, metastatic status, and chemotherapy use were each significantly correlated with the likelihood of receiving RT (all P < 0.05). Longer survival was exhibited in overall molecular subtypes who received RT(P<0.001). RT significantly improved outcomes in IBC cases of the hormone receptor (HR)-/human epidermal growth factor (HER2)- phenotype (OR, odds ratio = 0.525 [0.334&ndash;0.823], P = 0.005), whereas those with HR+/HER2-, HR+/HER2+ or HR-/HER2+ subtypes had a comparable prognosis between the RT cohort and non-RT cohort. HR-/HER2- patients with pathologic stage N0-2M0 had longer survival with RT (OR=0.354 [0.178-0.704], P=0.003), whereas those with N3M0 stage (P=0.880) or M1 stage (P=0.443) derived no benefit. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion: </span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Marked improvements in survival following RT were noted for HR&minus;/HER2&minus; IBC with pathologic N0&ndash;2M0 staging.</span></span></span></span></span></span></span></span></span></div> Inflammatory breast neoplasms, radiotherapy, survival analysis, retrospective studies, SEER program. 913 919 http://ijrr.com/browse.php?a_code=A-10-1-1415&slc_lang=en&sid=1 Z.H. Zhang 7900319475328460032344 7900319475328460032344 No Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, P. R. China Y.Y. Li 7900319475328460032345 7900319475328460032345 No Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, P. R. China Z.Y. He hezhy2253@163.com 7900319475328460032346 7900319475328460032346 Yes Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, P. R. China